Holen Sie sich die Stockscreener-App
27.98
1.78%
0.395
Schlusskurs vom Vortag:
$27.59
Offen:
$27.32
24-Stunden-Volumen:
520.16K
Relative Volume:
0.30
Marktkapitalisierung:
$2.84B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-15.46
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+0.57%
1M Leistung:
-11.03%
6M Leistung:
+68.75%
1J Leistung:
-7.72%
1-Tages-Spanne:
$27.06
$28.35
1-Wochen-Bereich:
$26.20
$28.50
52-Wochen-Spanne:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.95 | 2.80B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.79 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.93 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Analyst bullish on Beam Therapeutics (BEAM) over drug program trajectory - MSN
Beam Therapeutics (NASDAQ:BEAM) Upgraded at Canaccord Genuity Group - MarketBeat
Canaccord Genuity Initiates Coverage of Beam Therapeutics (BEAM) with Buy Recommendation - Nasdaq
Canaccord Genuity initiates Beam Therapeutics stock with buy rating - Investing.com UK
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Why Beam Therapeutics Inc. stock appeals to analystsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - mfd.ru
Canaccord Genuity Initiates Coverage on BEAM with a 'Buy' Rating - GuruFocus
Canaccord Genuity initiates Beam Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - TradingView
Growth Recap: Can Beam Therapeutics Inc sustain its profitabilityWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Aug EndMonth: Should I trade or invest in MAG Silver CorpJuly 2025 Reactions & Entry and Exit Point Strategies - baoquankhu1.vn
Ideas Watch: Is Cosmos Health Inc in a consolidation phase2025 Major Catalysts & Accurate Trade Setup Notifications - baoquankhu1.vn
13 Hot Stocks to Buy with the Highest Upside Potential - Insider Monkey
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory - Finviz
Readystate Asset Management LP Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat
Analyst Calls: Is ICCC backed by strong institutional buyingM&A Rumor & Breakout Confirmation Trade Signals - baoquankhu1.vn
Here is Why Beam Therapeutics (BEAM) Appears so Attractive - Insider Monkey
Assessing Beam Therapeutics (BEAM) Valuation After FDA Expedited Pathway And New Gene‑Editing Patent License - Yahoo Finance
17 Biotechnology Stocks with More Than 50% Upside - Insider Monkey
Why Beam Therapeutics (BEAM) Is Up 5.3% After New Gene-Editing IP Deal And FDA Fast Track - Yahoo Finance
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval - Insider Monkey
13 Best Innovative Stocks to Buy According to Wall Street Analysts - Insider Monkey
Beam Therapeutics Secures Standby License for Key Patents - The Globe and Mail
Wedbush Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Prime Editing and CRISPR Market Set for Explosive Growth at 24.1% - openPR.com
Trading Recap: Can Beam Therapeutics Inc sustain its profitabilitySell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
Best CRISPR Companies to Buy in 2026 and How to Invest in Them - The Motley Fool
Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (BEAM) - Stock Traders Daily
Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn
FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus
What’s the outlook for Beam Therapeutics Inc.’s sectorJuly 2025 Levels & Fast Gain Swing Trade Alerts - mfd.ru
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Biotech Innovator with 73% Potential Upside - DirectorsTalk Interviews
Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics announces upcoming board member resignation - TipRanks
Director Carole Ho to leave Beam Therapeutics (NASDAQ: BEAM) board - Stock Titan
Bear Alert: Can Beam Therapeutics Inc. sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Critical Year for Clinical Validation - AD HOC NEWS
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Avoiding Lag: Real-Time Signals in (BEAM) Movement - Stock Traders Daily
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM - MarketBeat
Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold - MarketBeat
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) - Finviz
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ARK Investment Acquires 116K Shares of Beam Therapeutics (BEAM) - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Look at the 46.90% Potential Upside and Cutting-Edge Genetic Medicine Advancements - DirectorsTalk Interviews
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beam Therapeutics Inc-Aktie (BEAM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Jan 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Jan 29 '26 |
Sale |
29.38 |
25,000 |
734,582 |
986,667 |
| Evans John M. | CEO |
Jan 30 '26 |
Sale |
28.36 |
25,000 |
708,946 |
986,667 |
0.88%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):